الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 199 |  |  |
| | | from | 199 | | |
Abstract
Background: NHLs are chemosensitive diseases can be cured with aggressive chemotherapy. IPI and other biological and molecular features are used in everyday practice to determine the different risk groups of lymphoma so that chemotherapy could be planned. There is a good association between serum interleukin 2 receptor (sCD25) level and tumor burden Soluble CD25 was considered the most sensitive serum marker for tumor burden in lymphomas. Objectives: The aim of this work was to evaluate the prognostic significance of soluble CD25 in newly diagnosed aggressive NHL patients and its relation to response to standard chemotherapy protocol. Furthermore clinical staging and IPI were correlated. Methods: The study was conducted on 25 patients with newly diagnosed aggressive NHL (REAL), in addition to 10 apparently healthy adult was selected as control group. All cases included in this study received standar CHOP protocol and serum soluble CD25 was measured before and after 4 cycles of CHOP. Results: Out of 25 patients of NHL in this work, 20 cases were DLCL, 3 cases were follicular large cells, 2 cases were anaplastic large cell lymphoma. After the 4th cycle of CHOP those patients were evaluated for the clinical response, 12 cases achieved CR, 8 cases achieved PR, and 5 cases did not respond to CHOP protocol. sCD25 was significantly higher in NHL patients than controls. sCD25 was significantly elevated in advanced stages (III,IV) than early stages (I,II), also sCD25 was significantly elevated in IPI high and high intermediate risk groups than in low and low intermediate risk groups. Our study showed that in NHL patients high levels of sCD25 were strongly associated with poor prognostic parameters such as older age and poor PS. Also sCD25 was significantly correlated with LDH and B2M levels, 1st hour ESR, 2nd hour ESR, and negatively correlated with hemoglobin concentration in this work. In this work, initial sCD25 was significantly higher in NR and PR patients than CR patients and after chemotherapy this levels significantly decreased in CR patients and less in PR patients with no significant change in NR patients. sCD25 is at least as if not more sensitive than LDH as regard clinical stage, IPI and performace score and more sensitive than B2M as regard IPI and performace score.While, B2M correlated with the clinical stage more than sCD25. Conclusions: sCD25 is a valuable prognostic factor in NHL and could be useful for monitoring the responsiveness.